Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the 'Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results' (LEADER) trial

被引：0
|
作者：
Bain, S. [1 ]
Zinman, B. [2 ]
Marso, S. P. [3 ]
Christiansen, E. [4 ]
Calanna, S. [4 ]
Rasmussen, S. [4 ]
Buse, J. B. [5 ]
机构：
[1] Univ Swansea, Sch Med, Swansea, W Glam, Wales
[2] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[3] Res Med Ctr, Kansas City, MO USA
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ N Carolina, Sch Med, Chapel Hill, NC USA
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A17
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
    Crowley, Matthew J.
    McGuire, Darren K.
    Alexopoulos, Anastasia-Stefania
    Jensen, Thomas Jon
    Rasmussen, Soren
    Saevereid, Hans A.
    Verma, Subodh
    Buse, John B.
    DIABETES CARE, 2020, 43 (09) : E108 - E110
  • [32] Severe hypoglycaemia shown to be a major risk factor for cardiovascular death in patients with type 1 diabetes
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2014, 16 (11): : 1181 - 1181
  • [33] Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2020, 132 (04) : 314 - 319
  • [34] Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
    William Hinton
    Michael Feher
    Neil Munro
    Simon de Lusignan
    Diabetes Therapy, 2018, 9 : 1397 - 1402
  • [35] Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
    Hinton, William
    Feher, Michael
    Munro, Neil
    de Lusignan, Simon
    DIABETES THERAPY, 2018, 9 (03) : 1397 - 1402
  • [36] Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke Post Hoc Analysis From the LEADER Trial
    Verma, Subodh
    Poulter, Neil R.
    Bhatt, Deepak L.
    Bain, Stephen C.
    Buse, John B.
    Leiter, Lawrence A.
    Nauck, Michael A.
    Pratley, Richard E.
    Zinman, Bernard
    Orsted, David D.
    Fries, Tea Monk
    Rasmussen, Soren
    Marso, Steven P.
    CIRCULATION, 2018, 138 (25) : 2884 - 2894
  • [37] Relationship between hypoglycaemia, cardiovascular outcomes, and empagilflozin treatment in the EMPA-REG OUTCOME® trial
    Fitchett, David
    Inzucchi, Silvio E.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Vedin, Ola
    Zinman, Bernard
    Johansen, Odd Erik
    EUROPEAN HEART JOURNAL, 2020, 41 (02) : 209 - 217
  • [38] Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
    Nauck, Michael A.
    Tornoe, Karen
    Rasmussen, Soren
    Treppendahl, Marianne Bach
    Marso, Steven P.
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (05): : 465 - 468
  • [39] Hypoglycaemia is associated with increased risk of cardiovascular events: results from the EXAMINE trial
    Heller, S. R.
    Bergenstal, R.
    Cannon, C. P.
    Kupfer, S.
    Wilson, C.
    White, W. B.
    DIABETOLOGIA, 2016, 59 : S44 - S44
  • [40] Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
    Verma, S.
    Bain, S. C.
    Bhatt, D. L.
    Leiter, L. A.
    Mazer, C. D.
    McGuire, D. K.
    Pratley, R.
    Zinman, B.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Buse, J. B.
    DIABETOLOGIA, 2019, 62 : S560 - S560
12345